Sling Therapeutics raises $123 million to advance thyroid eye disease drug

Sling Therapeutics raises $123 million to advance thyroid eye disease drug

Sling banks $123M for an experimental thyroid eye disease pill

A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.

Sling Therapeutics Announces $123 Million Series C Financing to Advance ...

Sling ropes in $123m for oral thyroid eye disease drug

Sling Therapeutics has raised $123m to propel its thyroid eye disease (TED) pill through a pivotal clinical trial. The funds, which were raised in a Series C round, will help the biotech evaluate linsitinib in an ongoing Phase III trial. In a separate announcement alongside the financing, Sling…

Roundup: Sling Therapeutics Closes $123 Million Series C Financing, Circle Pharma Announces $92.5 Million Series E Financing

Sling Therapeutics closes a $123 million Series C to advance linsitinib, while Circle Pharma raises an oversubscribed $92.5 million Series E to move CID-165, into clinical development for ER-positive breast cancer.

Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease

Investors are pumping $123 million into a tiny Michigan biotech that is resurrecting an Astellas cancer drug for an eye disease that has attracted lots of VC and pharma attention in recent years. Sling Therapeutics ...